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Background: Myotonic dystrophy type 1 (DM1) is an autosomal dominant genetic multisystem disorder and the
commonest adult-onset form of muscular dystrophy. DM1 results from the expansion of an unstable trinucleotide
cytosine-thymine-guanine (CTG) repeat mutation. CTG repeats in DM1 patients can range from 50 to several thousands,
with a tendency toward increased repeats with successive generations (anticipation). Associated findings can include
involvements in almost every systems, including the brain, and cognitive abnormalities occur in the large majority of
patients. The objectives are to describe and compare the intellectual abilities of a large sample of DM1 patients with
mild and classic adult-onset phenotypes, to estimate the validity of the Wechsler Adult Intelligence Scale-Revised
(WAIS-R) in DM1 patients with muscular weakness, and to appraise the relationship of intelligence quotient (IQ) to CTG
repeat length, age at onset of symptoms, and disease duration.
Methods: A seven-subtest WAIS-R was administered to 37 mild and 151 classic adult-onset DM1 patients to measure
their Full-Scale (FSIQ), Verbal (VIQ) and Performance IQ (PIQ). To control for potential bias due to muscular weakness,
Standard Progressive Matrices (SPM), a motor-independent test of intelligence, were also completed.
Results: Total mean FSIQ was 82.6 corresponding to low average IQ, and 82% were below an average intelligence.
Mild DM1 patients had a higher mean FSIQ (U=88.7 vs 81.1, p<0.001), VIQ (U=87.8 vs 82.3, p=0.001), and PIQ (U=94.8 vs
83.6, p<0.001) than classic adult-onset DM1 patients. In both mild and classic adult-onset patients, all subtests mean
scaled scores were below the normative sample mean. FSIQ also strongly correlate with SPM (rs=0.67, p<0.001),
indicating that low intelligence scores are not a consequence of motor impairment. FSIQ scores decreased with
both the increase of (CTG)n (rs=−0.41, p<0.001) and disease duration (rs=−0.26, p=0.003).
Conclusions: Results show that intellectual impairment is an extremely common and important feature in DM1,
not only among the classic adult-onset patients but also among the least severe forms of DM1, with low IQ scores
compared to general reference population. Health care providers involved in the follow-up of these patients should be
aware of their intellectual capacities and should adapt their interventions accordingly.
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Contexte: La dystrophie myotonique de type 1 (DM1) est une maladie génétique à transmission autosomique
dominante et la dystrophie musculaire la plus fréquemment diagnostiquée chez l’adulte. Elle résulte d’une
répétition instable d’un trinucléotide cytosine-thymine-guanine (CTG). Le nombre de CTG peut varier de 50 à plusieurs
milliers. Elle affecte pratiquement tous les systèmes, incluant le cerveau, et des déficits cognitifs surviennent chez une
majorité de patients. Les objectifs sont de décrire et comparer les capacités intellectuelles d’un large échantillon de
patients atteints de la forme légère et adulte-classique de DM1, d’estimer la validité de l’Échelle d’intelligence de
Wechsler-Révisée (WAIS-R) chez des patients présentant une faiblesse musculaire, et d’évaluer la relation entre le
quotient intellectuel (QI) et le nombre de CTG, l’âge d’apparition des symptômes et la durée de la maladie.
Méthodes: Un WAIS-R à sept sous-tests fut administré à 37 patients légers et 151 adultes-classiques pour estimer leur
QI global, Verbal et Performance. Afin de contrôler des biais potentiels liés à la faiblesse musculaire, les Matrices de
Raven ont également été complétées.
Résultats: Au total, le QI global moyen était de 82.6, correspondant à un QI situé dans la moyenne faible, et 82% a
obtenu un QI global inférieur à une intelligence moyenne. Les patients légers ont obtenu des résultats moyens
supérieurs aux patients adultes-classiques au QI global (U = 88.7 vs 81.1, p < 0.001), Verbal (U = 87.8 vs 82.3, p = 0.001)
et Performance (U = 94.8 vs 83.6, p < 0.001). Pour les deux groupes, les scores moyens aux sous-tests étaient tous situés
sous la moyenne normative. Le QI global corrèle fortement avec les Matrices (rs = 0.67, p < 0.001), ce qui montre que
l’atteinte musculaire n’influence pas la mesure de l’intelligence. Le QI global diminue avec l’augmentation des CTG
(rs = -0.41, p < 0.001) et la durée de la maladie (rs = -0.26, p = 0.003).
Conclusions: L’altération du fonctionnement intellectuel marquée par de faibles QI est une caractéristique importante
et extrêmement fréquente dans la DM1, non seulement dans la forme adulte-classique, mais également dans la forme
moins sévère. Les professionnels de la santé impliqués dans le suivi de ces patients devraient tenir compte de leurs
capacités intellectuelles et adapter leurs interventions en conséquence.
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Myotonic dystrophy type 1 (DM1) is an autosomal dom-
inant genetic disorder with high but incomplete pene-
trance and the commonest adult-onset form of muscular
dystrophy. As a muscle disease, DM1 is characterized by
an inability to relax voluntary muscle contractions (myo-
tonia) and by progressive distal to proximal muscle
weakness. Associated findings can include involvements
in almost every systems such as the cardiac, respiratory,
gastrointestinal, endocrine, ocular, and central nervous
system (CNS) [1]. DM1 results from the expansion of an
unstable trinucleotide cytosine-thymine-guanine (CTG)
repeat mutation located in the 3′ untranslated region of
a gene (19q13.3) encoding a putative protein kinase
(DMPK) [2]. When transcribed into CUG-containing
RNA, mutant transcripts aggregate as nuclear foci that
sequester RNA-binding proteins, including members of
the muscleblind (MBNL) family, resulting in a spliceopa-
thy of downstream effector genes [3]. CTG repeats in
DM1 patients can range from 50 to several thousands,
with a tendency toward increased repeats with succes-
sive generations (anticipation). The length of the CTG
repeats is partly correlated to the severity of the disease
and the age at onset of symptoms [4]. Considering vari-
ous European populations, the worldwide prevalence of
DM1 could be estimated at 5–20 per 100 000 [1]. In2010, the highest prevalence reaches 158 per 100 000 in
the Saguenay-Lac-Saint-Jean (SLSJ) region located in the
eastern part of the province of Quebec (Canada) [5].
Involvement of the CNS occurs in the large majority
of patients with DM1 [1,6,7], particularly when symp-
toms appear early in life. This can range from a condi-
tion of intellectual disability (a characteristic often
associated with congenital DM1 in which symptoms are
manifest from birth), to behavioural changes (e.g. re-
duced initiative, inactivity, apathetic temperament) [1].
Higher cognitive function disabilities are variably im-
paired [7-13] but a trend toward reduced frontal lobe
performances has often been reported, along with many
significant brain changes (e.g. brain atrophy, cell loss, ven-
tricular enlargement, diffuse white matter lesions as well as
significant cerebral blood flow reduction in frontotemporal
lobe regions) [1,14]. Excessive daytime sleepiness is a
prominent feature of DM1 and is most often considered as
independent from respiratory dysfunction or nocturnal
sleep disruption [15,16]. Moreover, psychopathological dis-
turbances such as avoidant, dependent and paranoid per-
sonality traits are frequent in adult form of DM1 [17,18].
Neuropsychological studies have shown evidences for a
generally lower intelligence level in the DM1 population
as compared to normal control subjects [13,14,19-21],
with no clear evidence of a progressive intellectual decline
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lectual impairment has been reported in studies that have
included both patients with adult and congenital onset of
DM1, even if it is commonly accepted that this latter form
is usually characterized by significantly lower intelligence
quotients (IQs) [8]. Moreover, classic IQ measures, as ob-
tained by the Wechsler Adult Intelligence Scale-Revised
(WAIS-R) [24,25] may potentially vary with the exam-
inee’s physical abilities. As the degenerative and progres-
sive muscles affection is an important feature of muscular
dystrophies, one may argue that lower WAIS-R scores
could partly relate to muscular weakness, muscular atro-
phy or myotonia [25].
The objectives of the present study are thus to de-
scribe and compare the intellectual abilities of a large
sample of DM1 patients with mild and classic adult-
onset phenotypes, to estimate the validity of the WAIS-
R for the evaluation of intelligence in DM1 patients with
muscular weakness, and to appraise the relationship of
IQ to CTG repeat length, age at onset of symptoms, and
disease duration. Since the striking increase of individ-
uals with a mild phenotype of DM1 in relationship with
the availability of genetic counselling and predictive test-
ing [5], it is relevant to better characterize these milder
patients as they will represent a very common phenotype
of DM1 population in a near future.
Methods
Participants
The cohort design included 188 DM1 patients (72 men
and 116 women, age range 20–80 years) selected from a
study population of 416 mild and classic adult-onset
DM1 patients listed at the Saguenay Neuromuscular
Clinic registry (Quebec, Canada). Any patient presenting
the congenital or childhood onset form of DM1 was ex-
cluded, as well as individual with other neurological dis-
eases. Inclusion criteria were age 18 years old or older
and being able to give a written informed consent. Study
participants were examined by a physiotherapist and had
their muscular impairment categorized according to the
Muscular Impairment Rating Scale (MIRS) [26]: grade 1,
no muscular impairment (n = 10, 5.3%): grade 2, minimal
signs (n = 31, 16.5%); grade 3, distal weakness (n = 36,
19.1%); grade 4, mild to moderate proximal weakness
(n = 91, 48.4%); grade 5, severe proximal weakness (n = 20,
10.6%). A patient was considered as having the mild
phenotype of DM1 when presenting at least two of the
following three criteria: 1- Less than 200 CTG repeats;
2- MIRS grade 1 or 2; 3- Age at onset over 40 years
old. To make sure of the accuracy of the information,
age at onset of symptoms was noted only if it was pre-
cisely and unequivocally given by the patient (n = 135).
For each participant, the diagnosis was confirmed by a mo-
lecular analysis. Mild and classic adult-onset phenotypeswere respectively present in 37 (19.7%) and 151 (80.3%)
participants. The frequency of the mild phenotype in this
patient sample is representative of the entire baseline
population at the time of the study [5]. All participants
agreed to be visited at home by a neuropsychologist who
administered and scored all tests. The evaluation took
place in two separate half days in order to minimize mental
fatigue. The schedule of testing was standardized across
the two days and each participant received the same se-
quence of testing in order to follow a standardized
protocol. Further details regarding this sample as well
as the design and survey instruments used are pub-
lished elsewhere [15,27,28]. This study was approved by
the Institutional Review Board of the Centre de santé et
de services sociaux de Chicoutimi (Quebec, Canada).
Neuropsychological measures
Wechsler adult intelligence scale-revised (WAIS-R)
Intellectual functioning was evaluated using the French
adaptation for the seven-subtest short form of the
WAIS-R, given the fact that French is the first language
of all participants [24,29,30]. The test is composed of the
Information, Digit Span, Arithmetic, and Similarities
subtests of the Verbal scale, and of the Picture Completion,
Block Design, and Digit Symbol subtests of the Perform-
ance scale. The ordinary, non age-corrected scaled scores
are included into algorithms to prorate the weighted sums
of Verbal and Performance scaled scores [29]. United
States (US) adult population-based norms were used. The
mean ± SD is 100 ± 15 for the IQ indices, and 10 ± 3 for
the subtests scaled scores [24]. The composite reliability
estimates of VIQ, PIQ, and FSIQ for the seven-subtest
short form are respectively .96, .94, and .97 compared to
the entire WAIS-R [29].
The administration of every subtests was not possible
for 29 patients (11 men, 18 women; aged between 32
and 77 years; 22 classic adult-onset and 7 mild pheno-
type; (CTG)n ranging from 50 to 1900), mostly due to
fatigue reported by the patients themselves and caused
by a sustained mental effort throughout the overall
evaluation protocol. However, in these cases, the compu-
tation of the estimated FSIQ score was still possible by
using a three-subtest short form, based on the adminis-
tration of the Information, Digit Span, and Picture Com-
pletion subtests [31]. The composite reliability estimates
of FSIQ using these three subtests is excellent (.91) [31],
even if this combination does not permit the calculation
of a prorated VIQ and PIQ.
Raven’s standard progressive matrices (SPM)
To make sure that low WAIS-R FSIQ measures in DM1
patients are unlikely to represent a bias due to muscular
weakness of the upper limbs, the SPM [32] were also ad-
ministered. The SPM is a widely used intelligence test
Table 1 Clinical profile of patients with DM1
Characteristics Total Classic
adult-onset
Mild P value
n =188 n =151 n =37
Age, y 45.7 ± 11.0 43.5 ± 9.0 54.9 ± 13.7 <0.001
Sex M:F 72:116 60:91 12:25 n.s.
Education, y 9.9 ± 2.6 9.8 ± 2.5 10.3 ± 2.7 n.s.
Age at onset, ya 21.6 ± 9.4 20.4 ± 7.6 43.7 ± 12.8 <0.001
Disease duration, ya 22.4 ± 8.9 23.0 ± 8.5 10.0 ± 5.4 <0.001
(CTG)n 811.3 ± 524.5 973.3 ± 449.2 149.8 ± 168.0 <0.001
MIRS 3.4 ± 1.1 3.7 ± 0.8 2.3 ± 1.1 <0.001
Mean ± SD.
DM1 =Myotonic Dystrophy type 1; (CTG)n = Cytosine-Thymine-Guanine
repeats size;
MIRS = Muscular Impairment Rating Scale.
aData available for 135 DM1 patients; 128 classic adult-onset and 7 mild form.
Table 2 WAIS-R IQs of patients with DM1
WAIS-R IQs Total Classic
adult-onset
Mild P value
n =188 (159a) n =151 (129a) n =37 (30a)
FSIQ 82.6 ± 8.4 81.1 ± 7.5 88.7 ± 9.2 <0.001
VIQ 83.4 ± 9.1 82.3 ± 9.0 87.8 ± 8.5 0.001
PIQ 85.7 ± 10.2 83.6 ± 8.2 94.8 ± 12.8 <0.001
VIQ-PIQ
discrepancies
7.9 ± 6.3 7.2 ± 6.0 10.8 ± 6.7 0.002
Mean ± SD.
WAIS-R =Wechsler Adult Intelligence Scale-Revised; IQ = Intelligence Quotient;
DM1 =Myotonic Dystrophy type 1; FSIQ = Full-Scale IQ; VIQ = Verbal IQ;
PIQ = Performance IQ.
aValid N for VIQ and PIQ indices.
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many studies have demonstrated the SPM’s efficacy as a
measure of general intelligence by showing strong posi-
tive correlations with the Wechsler tests [33]. Predicted
WAIS-R FSIQ (FSIQ’) scores were derived from total
raw scores on the SPM using a regression equation [34].
Statistical analyses
Mann–Whitney U Test was used as most of the data did
not meet the assumption of normal distribution. One-
sample t-test was used to determine whether two distribu-
tions of the same sample of DM1 patients were different
one from another. The degree of the linear relationship
between two variables was assessed by Spearman’s correl-
ation. Finally, chi-square tests were used to compare the
frequency of cases between two categorical variables. Stat-
istical significance was assumed at the level of p < 0.05.
Data were analysed using the IBM SPSS Statistics version
20 for Mac OS.
Results
DM1 participants
From the 416 DM1 patients listed at the Saguenay
Neuromuscular Clinic registry, a total of 82 (19.7%) were
excluded from the study for reasons such as no longer
lives in the SLSJ region (36.6%), incorrect contact infor-
mation (25.6%), refusing clinical follow-up (20.7%), and
suffering from another major health problem (17.1%).
Another group of 131 (31.5%) potential participants re-
fused to participate. Of these, 77 (58.8%) were not inter-
ested, 28 (21.4%) invoked employment, health or time
issues, 16 (12.2%) had speech or mobility limitations,
and 10 (7.6%) gave other reasons. Of the 203 (48.8%)
DM1 patients who consented to take part to the study, 3
dropped out. Comparisons between the 200 DM1 pa-
tients who participated in the study and the 216 nonpar-
ticipants showed no differences in terms of sex, CTG
repeat length, and proportion of mild versus classic
adult-onset phenotype of DM1, but the two groups
slightly differed in terms of age (47.0 ± 11.8 years vs 50.2
± 14.6 years respectively, p < 0.05). Finally, 12 partici-
pants did not underwent the WAIS-R (7 men and 5
women, 5 mild and 7 classic adult-onset phenotype, age
range 38–80 years, CTG repeat length range 90–1900,
education range 4–14 years).
Table 1 shows clinical characteristics of the cohort
study of 188 DM1 patients. As expected, mild phenotype
patients were significantly older and had a higher age at
onset of symptoms, a lower disease duration and a lower
number of CTG repeats than classic adult-onset pheno-
type patients. Years of education and the proportion of
men and women did not differ between groups. Com-
parisons between patients who completed the seven-
subtest short form of the WAIS-R (n = 159) and thosewho did not (n = 29), revealed that age, education, age at
onset of symptoms, disease duration, (CTG)n and MIRS
were not different, as well as for the proportion of men
and women, and mild and classic adult-onset pheno-
types of DM1. However, the DM1 patients who did not
complete the WAIS-R obtained a lower FSIQ (77.4 vs
83.6, p < 0.001).
Wechsler adult intelligence scale-revised
Tables 2 and 3 present WAIS-R IQs and the mean
scaled scores of the seven WAIS-R subtests of DM1 pa-
tients with mild and classic adult-onset forms. WAIS-R
FSIQ scores ranged from 61 to 119, with a median score
of 82. For both mild and classic adult-onset phenotypes,
all three mean IQ indices are below the general popula-
tion mean (except for PIQ in the mild group). Despite
their low mean IQs, the mild form group had a higher
mean FSIQ, a higher mean VIQ, and a higher mean PIQ
compared to the classic adult-onset form group. Irre-
spectively of the DM1 form, all subtests mean scaled
scores are below the normative sample mean. On the
other hand, results indicate that mild phenotype patients
had a higher performance than classic adult-onset
Table 3 Comparisons of mean scaled scores for the seven-subtest WAIS-R in classic adult-onset and mild DM1 patients
Scale Subtest Total Classic adult-onset Mild P value
Verbal Information 6.5 ± 1.8 (187) 6.3 ± 1.8 (151) 7.0 ± 2.1 (36) n.s.
Digit Span 6.0 ± 2.4 (188) 5.7 ± 2.4 (151) 6.8 ± 2.3 (37) 0.045
Arithmetic 7.5 ± 2.4 (179) 7.2 ± 2.3 (144) 8.6 ± 2.3 (35) 0.004
Similarities 7.0 ± 2.2 (168) 6.9 ± 2.2 (135) 7.1 ± 2.1 (33) n.s.
Performance Picture Completion 6.7 ± 2.2 (188) 6.6 ± 2.1 (151) 7.1 ± 2.5 (37) n.s.
Block Design 6.3 ± 2.2 (186) 6.0 ± 2.0 (150) 7.5 ± 2.6 (36) <0.001
Digit Symbol 6.6 ± 2.1 (187) 6.5 ± 2.0 (150) 6.9 ± 2.5 (37) n.s.
Mean Scaled Scores ± SD (n).
WAIS-R =Wechsler Adult Intelligence Scales-Revised; DM1 =Myotonic Dystrophy type 1.
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Design subtests (Table 3).
Table 2 also shows the absolute VIQ-PIQ mean dis-
crepancies, ranging from 0 to 29, and from 0 to 31 for
mild and classic adult-onset DM1 patients, respectively.
The former showed a greater variability in their PIQ
scores (72 to 124) as compared with the classic adult-
onset DM1 patients (65 to 111). Conversely, the mild
group showed a lesser variability in their VIQ scores (68
to 112) than classic adult-onset DM1 patients (58 to 109).
All this could explain the higher VIQ-PIQ mean discrep-
ancies in favour of the mild DM1 patients. Altogether, re-
sults suggest that the mean PIQ of DM1 patients is
significantly higher (p < 0.01) than the mean VIQ. More-
over, the VIQ-PIQ discrepancies were in favour of a
PIQ > VIQ pattern for more than 60% of the total sam-
ple (n = 159). Finally, about 15% of all DM1 patients
showed a difference of 15 points (one SD) or more be-
tween their VIQ and PIQ scores.
Figure 1 illustrates the distribution of intelligence
levels based on WAIS-R FSIQ scores for mild and clas-
sic adult-onset DM1 patients. This figure shows a clearFigure 1 Distribution of intelligence levels based on WAIS-R FSIQ in clasasymmetry in both FSIQ distributions towards a left-
sided displacement compared to normal sample. More
particularly, classification of FSIQ scores showed that
87.4% of the classic adult-onset and 59.4% of the mild
DM1 patients were below the average range (90–109) of
intellectual functioning. Figure 1 further shows that the
proportion of classic adult-onset DM1 patients scoring
in the WAIS-R retarded range of intellectual function-
ing is more than twice the proportion of the normal
population.
Figures 2 and 3 present the relationship between
WAIS-R FSIQ and CTG repeats size and disease dur-
ation for the total sample. There is a statistical signifi-
cant decline in FSIQ scores with both the increase of the
(CTG)n (rs = −0.41, p < 0.001) and the disease duration
(rs = −0.26, p = 0.003), even if they are considered moder-
ate and weak correlation, respectively [35]. Finally, FSIQ
was not linked to the age at onset of symptoms.
Standard progressive matrices
Table 4 compares the distributions of the WAIS-R diag-
nostic labels according to FSIQ measurement and SPMsic adult-onset and mild DM1 patients compared to normal sample.
Figure 2 Correlation analysis between WAIS-R FSIQ and CTG
repeats size in patients with DM1.
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WAIS-R FSIQ and the SPM estimation are 82.6 ± 8.4
and 81.4 ± 7.8, respectively. Except for one case (Average
90-109), there are no significant differences between mean
WAIS-R FSIQ and mean SPM estimation within each
diagnostic labels. Moreover, there is a strong significant
correlation between these two measures of intelligence for
the whole sample (rs = 0.67, p < 0.001), and within each
subgroup of DM1 patients (mild: rs = 0.43, p = 0.007;
classic adult-onset: rs = 0.70, p < 0.001).
Discussion
This study evaluated the intellectual abilities of a large
sample of DM1 patients with mild and classic adult-
onset forms. Reduced intelligence associated with DM1
has been mentioned in many studies including the first
descriptions of the disease [36]. Intellectual impairment
of different degrees has been described in previous re-
ports but some of them can be criticized for as being
biased relatively to the inclusion of congenital DM1 pa-
tients or small sample sizes [8-10,12,37]. The present
study offers more reliable estimates of intellectual func-
tioning as we used a large and uniform cohort of DM1
patients with mild and classic adult-onset phenotypes,
with the exclusion of any congenital or childhood onset
patients. Our results first demonstrate that intelligenceFigure 3 Correlation analysis between WAIS-R FSIQ and disease
duration in patients with DM1.level of mild and classic adult-onset DM1 patients is
characterized by a low general intellectual functioning in
both verbal and nonverbal abilities. For our total sample
(n = 188), the mean WAIS-R FSIQ was 82.6, correspond-
ing to low average IQ according to Wechsler [24]. By
comparison, a study including 17 classic adult-onset
DM1 patients gave similar results on a full WAIS ad-
ministration, with a FSIQ of 85.3 (VIQ = 87.2; PIQ =
84.1) [19]. Moreover, a recent report [21] on a sample of
121 DM1 patients revealed a mean IQ of 85.0 on an ab-
breviated WAIS-III, which is also similar to our results.
It should nonetheless be mentioned that this latter study
included 7.9% of juvenile phenotype. Our findings also
contrasted with other previous studies of classic DM1
patients reporting a mean total FSIQ of 94.2 (n = 37)
[12], 95.0 (n = 47) [38] or 96.7 (n = 23) [39], which corre-
sponds to average intelligence levels. In addition, one
study reported a median FSIQ of 91 on 14 classic adult-
onset DM1 patients [40], while another observed a mean
FSIQ of 98.8 from a SPM calculation on 50 DM1 pa-
tients [41]. Our study does not validate these findings.
Regarding the FSIQ, standard deviations ranged from
+1.27 to −2.60 SD, and 64.4% (n = 121) had a FSIQ sig-
nificantly lower (>1 SD) than the normative sample
mean. Moreover, almost 5% of the patients obtained an
IQ in the intellectual disability range, which is more
than twice the percent of the WAIS-R standardization
sample. Only one patient had an IQ in the high average
range of intellectual functioning.
Studies that measured IQ in mild DM1 patients have
generally not detected any defect in global intelligence.
For example, a group of 36 late-onset DM1 patients
showed a mean SPM IQ of 107.4 [11], while 13 mild
form patients obtained a mean IQ of 98.9 (range 83–
116) on a two-subtest abbreviated WAIS-R [13]. In the
present study, 59.4% of our mild DM1 patients (n = 37)
were below the average range of intellectual functioning,
namely low average (n = 16, 43.3%), borderline (n = 5,
13.5%), and intellectual disability (n = 1, 2.7%). One
could argue that these divergent findings regarding mild
phenotype could be explained by differences in levels of
fatigue or excessive daytime sleepiness (EDS). To clarify
this issue, one of our previous study on the same cohort
of patients provide interesting data concerning clinical
correlates associated with presence or absence of fatigue
and/or EDS [15]. All DM1 participants were categorized
into four distinct groups according to their excessive fa-
tigue and EDS level. Post hoc comparisons showed that
FSIQ varies neither with excessive fatigue nor EDS sta-
tus. Another partial explanation may come from the
group of 29 patients who did not complete all subtests
of the WAIS-R short form. Their FSIQ scores were
based on a lower composite reliability estimates than the
one of the seven-subtest short form (.91 vs .97 compared
Table 4 Distributions of WAIS-R diagnostic labels according to WAIS-R FSIQ measurement and SPM FSIQ’ estimation in
DM1 patients
WAIS-R FSIQ SPM FSIQ’
(n =188) (n =187)
WAIS-R diagnostic labels Frequency Valid percent Mean ± SD Frequency Valid percent Mean ± SD p Valuea
Very superior (130 and above) _ _ _ _ _ _ _
Superior (120–129) _ _ _ _ _ _ _
High average (110–119) 1 0.5 119.0 _ _ _ _
Average (90–109) 33 17.6 94.6 ± 3.7 31 16.6 93.1 ± 3.0 0.008
Low average (80–89) 87 46.3 84.0 ± 2.7 72 38.5 84.5 ± 3.3 n.s.
Borderline (70–79) 58 30.9 75.3 ± 3.0 74 39.6 75.5 ± 2.8 n.s.
Deficiency (69 and below) 9 4.8 67.0 ± 2.8 10 5.3 66.9 ± 2.7 n.s.
WAIS-R =Wechsler Adult Intelligence Scales-Revised; FSIQ = Full-Scale IQ; SPM = Standard Progressive Matrices.
aDifferences between mean WAIS-R FSIQ and mean SPM FSIQ’ for each WAIS-R diagnostic labels were calculated using a one-sample t-test where the known value
was the corresponding mean WAIS-R FSIQ.
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FSIQ. Despite this previous assumption, we believe that
this could have a negligible impact on the results, con-
sidering the presence of only 7 mild DM1 patients in
that group, and an equal proportion of mild and classic
adult-onset phenotypes in both groups.
The definition of a mild phenotype of DM1 also varies
from one study to another. The original terminology by
Koch et al. [42] classified as “mild” patients those with
an age at onset over 40 years old. The definition used in
the present study took advantage of the deoxyribo-
nucleic acid (DNA) analysis results and is a combination
of a small expansion of CTG repeats, the absence of mus-
cular impairment or a late age at onset. From a clinical
perspective, the combined use of neuromuscular and gen-
etic criteria allow a more sensitive characterization of
these milder patients. Using a definition of mild cases
based only on a small expansion of less than 200 CTG re-
peats, we also observed many patients with FSIQ scores
below the average range of intellectual functioning as
shown in Figure 2. In all, our results strongly suggest that
intellectual impairment is an extremely common and im-
portant feature in DM1, not only among the classic adult-
onset patients but also among the least severe forms of
DM1, with low IQ scores compared to general reference
population.
Our DM1 patients also obtained significant low scores
on every WAIS-R subtests, with better scores on Digit
Span, Arithmetic, and Block Design for the mild group.
Moreover, we found a significant relationship between
FSIQ and (CTG)n. This can partly explain the fact that
the mild group of DM1 patients obtained higher IQ in-
dices. In fact, patients with more CTG repeats have a
lower IQ than those with smaller expansions (rs = −0.41,
p < 0.001). This is consistent with previous studies who
noted an association between higher CTG repeat size
and some cognitive impairment in classic adult-onsetDM1 patients [19,21,38]. Such significant negative rela-
tionships with FSIQ have also been described in severe
and mild congenital DM1 children [43] and childhood
[43,44] forms of DM1. In combination with these re-
ports, our study on classic adult-onset and mild DM1
portrays the natural course of this complex multisyste-
mic neuromuscular disorder throughout a clinical con-
tinuum in its CNS manifestations. We believe that these
results are further evidence of an existing overlap be-
tween the different phenotypes in DM1. From this point
of view, higher IQs and better scores on some subtests
in favour of the mild group of patients could rather re-
flect a later onset of the disease than a complete distinct
cognitive phenotype. We also found that FSIQ was not
linked to the age at onset of symptoms. For patients af-
fected by DM1, the symptoms reported at onset are usu-
ally myotonia, distal weakness or both [45]. In the
present study, the absence of such correlation suggests
that there is no close relationship between the muscular
involvement and the CNS impairment as measured by
the FSIQ. This suggestion of two separate processes in
DM1 evolution has also been recently described in a
study that analysed cerebrospinal fluid levels of three
biomarkers in patients with DM1, namely total tau
(T-tau), phosphorylated tau (P-tau) and 42-amino-
acid form of ß-amyloid (Aß42). Although the Aß42/P-tau
ratio was decreased in classic adult-onset DM1 patients,
along with a tendency of increased T-tau and P-tau levels,
the authors did not find any correlation between these
biomarkers and disease duration or severity of muscular
involvement [46]. DM1 is a progressive disease affecting
the muscles, but the question if CNS dysfunction in DM1
is also a progressive condition remains by cons uncertain.
It was suggested that progressive CNS dysfunction could
potentially account for cognitive decline rather than a true
neurodegenerative process per se [47]. The present results
showed that FSIQ scores significantly decreased with the
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the hypothesis of a certain global decline in cognitive
abilities in DM1 over time but needs to be confirmed
by longitudinal designs. A follow-up study (mean
follow-up: 7.3 ± 2.7 years) on 20 classic adult-onset
DM1 patients showed a specific and progressive impair-
ment in attentional capacities, without extension to
additional areas of cognition [22]. Over a four-year
period, another group of 34 DM1 patients (including 2
congenital forms and 32 classical forms with juvenile or
classic adult-onset) showed a significant deterioration
in linguistic functions, with a tendency towards decline
in executive abilities, confirming a predominant in-
volvement of cognitive functions subserved by fronto-
temporal areas of the brain [23].
It is well acknowledged that educational attainment is
highly correlated to psychometric measures of intelligence
[24]. In this context, as IQs between mild and classic
adult-onset DM1 patients are quite similar, it is not sur-
prising to observe that years of education are the same for
both groups. One of our previous study also demonstrated
a relationship between increased (CTG)n and higher risk
of material and social deprivation [27]. Thus, classic adult-
onset DM1 patients are more likely to show higher un-
employment, lower family income, and higher reliance on
social assistance compared with mild DM1 patients. One
could argue that this discrepancy of the social impact be-
tween mild and classic adult-onset DM1 patients is prob-
ably explained by the lower motor skills of the latter.
Since classic adult-onset DM1 patients obtained the low-
est IQs, with a high frequency in the intellectual disability
range, it is reasonable to believe that intellectual impair-
ment is an important contributing factor in the socio-
economic deprivation portrayed in patients with DM1
[27]. From our clinical experience, additional factors
such as daytime sleepiness, fatigue, personality traits,
apathy or other cognitive deficits could also contribute
to the vulnerability of these patients in experiencing so-
cioeconomic inequalities.
Intellectual evaluation, as for any neuropsychological
investigation, depends in some way on motor abilities,
which may be impaired in DM1. We used SPM as a
motor-independent test of intelligence to assess muscu-
lar impairment as a possible confounding factor in the
establishment of WAIS-R IQ indices. We found a strong
correlation between total WAIS-R and SPM FSIQ esti-
mation, both for the entire sample and within each sub-
group of DM1 patients. Moreover, our results showed a
discrepancy in favour of a significant higher mean PIQ
score compared to VIQ, added to a more frequent PIQ >
VIQ pattern. These results altogether suggest that the
WAIS-R is a valid instrument to evaluate global intelligence
in mild and classic adult-onset DM1 patients, on the one
hand, and that muscular weakness in DM1, particularly ofthe upper limbs, relates not to intellectual impairment,
on the other. Moreover, our results are in agreement
with a previous study showing that both verbal and
nonverbal WAIS subtests were consistently lower in a
group of classic adult-onset DM1 patients compared to
normal and neurological controls such as spinal muscle
atrophy, suggesting that cognitive impairment is not a
consequence of motor impairment [19].
This study has some limitations that should be ad-
dressed in future researches. First, assessment of adaptive
skills was not included. In addition to better characterize
our DM1 patients with very poor IQ scores, a complete
assessment of the adaptive behavior would have been use-
ful in determining how well these individuals respond to
daily demands from the environment. Also, our study
does not include unaffected family members of the house-
holds of the patient or case controls. Despite that our re-
sults are compared to population-based norms, the
inclusion of a family member unaffected by DM1 could
have clarified if low IQ scores are linked to the disease
or if they are a consequence of any socioeconomic
deprivation previously reported in DM1 population
[27]. In our study, IQ scores were obtained using the
French adaptation of the WAIS-R [30], although this
version is not validated in a French Canadian popula-
tion. A French European standardization sample exists
but we decided to use US norms since we consider that
these data are more likely to represent the intellectual
levels of North-American adults. A study who compared
the French and American WAIS-R standardization sam-
ples showed that the two are very similar, except for two
variables. Education level is slightly lower for the French
subjects, while the French sample included an age group
(75–79 years) that is missing from the American sample,
which leads to give a greater weight to the variable Age
[48]. Finally, whenever possible, future studies in DM1
could correlate their neuropsychological data to neuroim-
aging or functional investigations such as PET (positron
emission tomography) or SPECT (single-photon emission
computed tomography).
Conclusions
The impact of DM1 on brain and cognition is well de-
scribed. It is generally acknowledged that intelligence is
lower in this population as compared to normal control
subjects, and that intellectual disability is characteristic
of the congenital and childhood onset forms of the dis-
ease. Our findings showed that intellectual impairment
is an extremely common and important feature of DM1,
and could also be observed in individuals mildly affected
by DM1, with low IQ scores compared to the general
reference population. Since the introduction of predict-
ive DNA testing, the proportion of patients with a mild
phenotype is an increasing phenomenon in DM1 [5],
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these patients should be aware of their intellectual cap-
acities and should adapt their interventions accordingly.
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